Does the media favor BEAM or CLYM?

In the previous week, Climb Bio had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 16 mentions for Climb Bio and 13 mentions for Beam Therapeutics. Climb Bio's average media sentiment score of 0.61 beat Beam Therapeutics' score of -0.13 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Climb Bio 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, KOD or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is KOD or CLYM more profitable?

Climb Bio's return on equity of -35.60% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Climb Bio N/A -35.60% -34.41%

Does the media prefer KOD or CLYM?

In the previous week, Climb Bio had 8 more articles in the media than Kodiak Sciences. MarketBeat recorded 16 mentions for Climb Bio and 8 mentions for Kodiak Sciences. Climb Bio's average media sentiment score of 0.61 beat Kodiak Sciences' score of 0.57 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLYM or IMNM more profitable?

Climb Bio's return on equity of -35.60% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -35.60% -34.41% Immunome N/A -51.15% -47.32%

Does the media refer more to CLYM or IMNM?

In the previous week, Climb Bio had 12 more articles in the media than Immunome. MarketBeat recorded 16 mentions for Climb Bio and 4 mentions for Immunome. Immunome's average media sentiment score of 0.83 beat Climb Bio's score of 0.61 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLYM or RARE?

In the previous week, Ultragenyx Pharmaceutical had 8 more articles in the media than Climb Bio. MarketBeat recorded 24 mentions for Ultragenyx Pharmaceutical and 16 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.61 beat Ultragenyx Pharmaceutical's score of 0.36 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer NRIX or CLYM?

In the previous week, Nurix Therapeutics had 6 more articles in the media than Climb Bio. MarketBeat recorded 22 mentions for Nurix Therapeutics and 16 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.61 beat Nurix Therapeutics' score of 0.16 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Climb Bio 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Climb Bio (CLYM) Competitors

$14.00 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$13.72 -0.28 (-2.00%)

As of 08/7/2026 07:44 PM Eastern

Compare

CLYM vs. BEAM, KOD, IMNM, RARE, and NRIX

Should you buy Climb Bio stock or one of its competitors? MarketBeat compares Climb Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Climb Bio include Beam Therapeutics (BEAM), Kodiak Sciences (KOD), Immunome (IMNM), Ultragenyx Pharmaceutical (RARE), and Nurix Therapeutics (NRIX). These companies are all part of the "biotechnology" industry.

How does Climb Bio compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Beam Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

In the previous week, Climb Bio had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 16 mentions for Climb Bio and 13 mentions for Beam Therapeutics. Climb Bio's average media sentiment score of 0.61 beat Beam Therapeutics' score of -0.13 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Climb Bio	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus target price of $49.00, indicating a potential upside of 78.31%. Climb Bio has a consensus target price of $22.75, indicating a potential upside of 62.50%. Given Beam Therapeutics' higher probable upside, equities analysts plainly believe Beam Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Climb Bio	N/A	-35.60%	-34.41%

Climb Bio has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$156.04M	18.19	-$79.99M	-$0.86	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats Beam Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Climb Bio compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Climb Bio's return on equity of -35.60% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Climb Bio	N/A	-35.60%	-34.41%

Kodiak Sciences has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market.

In the previous week, Climb Bio had 8 more articles in the media than Kodiak Sciences. MarketBeat recorded 16 mentions for Climb Bio and 8 mentions for Kodiak Sciences. Climb Bio's average media sentiment score of 0.61 beat Kodiak Sciences' score of 0.57 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences currently has a consensus price target of $48.14, indicating a potential upside of 6.11%. Climb Bio has a consensus price target of $22.75, indicating a potential upside of 62.50%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats Kodiak Sciences on 10 of the 14 factors compared between the two stocks.

How does Climb Bio compare to Immunome?

Climb Bio (NASDAQ:CLYM) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Climb Bio had 12 more articles in the media than Immunome. MarketBeat recorded 16 mentions for Climb Bio and 4 mentions for Immunome. Immunome's average media sentiment score of 0.83 beat Climb Bio's score of 0.61 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Immunome has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Climb Bio currently has a consensus target price of $22.75, indicating a potential upside of 62.50%. Immunome has a consensus target price of $34.18, indicating a potential upside of 36.56%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Climb Bio has higher earnings, but lower revenue than Immunome. Climb Bio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Immunome	$4.02M	706.01	-$212.39M	-$2.38	N/A

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Climb Bio's return on equity of -35.60% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-35.60%	-34.41%
Immunome	N/A	-51.15%	-47.32%

Summary

Climb Bio beats Immunome on 9 of the 14 factors compared between the two stocks.

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Climb Bio (NASDAQ:CLYM) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Climb Bio currently has a consensus target price of $22.75, suggesting a potential upside of 62.50%. Ultragenyx Pharmaceutical has a consensus target price of $57.82, suggesting a potential upside of 123.17%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Climb Bio has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 8 more articles in the media than Climb Bio. MarketBeat recorded 24 mentions for Ultragenyx Pharmaceutical and 16 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.61 beat Ultragenyx Pharmaceutical's score of 0.36 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Climb Bio has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Climb Bio is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Ultragenyx Pharmaceutical	$673M	3.80	-$575M	-$5.84	N/A

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Climb Bio has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Climb Bio's return on equity of -35.60% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-35.60%	-34.41%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-43.78%

Summary

Climb Bio and Ultragenyx Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

How does Climb Bio compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Climb Bio has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Climb Bio's return on equity of -35.60% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Climb Bio	N/A	-35.60%	-34.41%

In the previous week, Nurix Therapeutics had 6 more articles in the media than Climb Bio. MarketBeat recorded 22 mentions for Nurix Therapeutics and 16 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.61 beat Nurix Therapeutics' score of 0.16 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Climb Bio	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.8% of Climb Bio shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nurix Therapeutics currently has a consensus price target of $34.00, indicating a potential upside of 33.18%. Climb Bio has a consensus price target of $22.75, indicating a potential upside of 62.50%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Nurix Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

Climb Bio has lower revenue, but higher earnings than Nurix Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	72.07	-$264.46M	-$3.45	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLYM vs. The Competition

Export

Metric	Climb Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$801.68M	$3.69B	$7.01B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-16.87	9.02	271.11	25.19
Price / Sales	N/A	1,303.70	597.74	81.69
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	4.17	18.10	13.25	6.22
Net Income	-$59.85M	-$13.25M	$3.45B	$342.66M
7 Day Performance	17.65%	6.24%	4.67%	4.41%
1 Month Performance	1.30%	-3.50%	-1.28%	-1.11%
1 Year Performance	723.53%	61.28%	77.33%	23.99%

Climb Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLYM Climb Bio	2.4381 of 5 stars	$14.00 flat	$22.75 +62.5%	+723.5%	$801.68M	N/A	N/A	9	News Coverage Earnings Report Analyst Forecast
BEAM Beam Therapeutics	2.0356 of 5 stars	$25.52 -3.7%	$46.85 +83.6%	+56.0%	$2.63B	$164.01M	N/A	510	News Coverage Earnings Report Analyst Downgrade
KOD Kodiak Sciences	1.5017 of 5 stars	$41.58 -2.2%	$42.14 +1.4%	+474.3%	$2.60B	N/A	N/A	90	News Coverage Positive News Upcoming Earnings
IMNM Immunome	3.2368 of 5 stars	$22.76 -1.4%	$33.17 +45.7%	+158.3%	$2.58B	$4.02M	N/A	40	Upcoming Earnings Insider Trade
RARE Ultragenyx Pharmaceutical	3.7392 of 5 stars	$24.91 -4.3%	$58.41 +134.5%	-5.9%	$2.45B	$673M	N/A	1,371	News Coverage Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLYM) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Competitors

CLYM vs. BEAM, KOD, IMNM, RARE, and NRIX

How does Climb Bio compare to Beam Therapeutics?

Summary

How does Climb Bio compare to Kodiak Sciences?

Summary

How does Climb Bio compare to Immunome?

Summary

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Summary

How does Climb Bio compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Climb Bio (CLYM) Competitors

CLYM vs. BEAM, KOD, IMNM, RARE, and NRIX

How does Climb Bio compare to Beam Therapeutics?

Do institutionals & insiders believe in BEAM or CLYM?

Which has more volatility & risk, BEAM or CLYM?

Does the media favor BEAM or CLYM?

Do analysts prefer BEAM or CLYM?

Is BEAM or CLYM more profitable?

Which has higher earnings & valuation, BEAM or CLYM?

Summary

How does Climb Bio compare to Kodiak Sciences?

Do institutionals and insiders believe in KOD or CLYM?

Is KOD or CLYM more profitable?

Which has more volatility and risk, KOD or CLYM?

Does the media prefer KOD or CLYM?

Do analysts prefer KOD or CLYM?

Which has better earnings & valuation, KOD or CLYM?

Summary

How does Climb Bio compare to Immunome?

Does the media refer more to CLYM or IMNM?

Which has more volatility and risk, CLYM or IMNM?

Do analysts prefer CLYM or IMNM?

Which has preferable earnings & valuation, CLYM or IMNM?

Do institutionals and insiders have more ownership in CLYM or IMNM?

Is CLYM or IMNM more profitable?

Summary

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Do analysts rate CLYM or RARE?

Which has more volatility & risk, CLYM or RARE?

Does the media prefer CLYM or RARE?

Which has better earnings and valuation, CLYM or RARE?

Do insiders & institutionals have more ownership in CLYM or RARE?

Is CLYM or RARE more profitable?

Summary

How does Climb Bio compare to Nurix Therapeutics?

Is NRIX or CLYM more profitable?

Does the media prefer NRIX or CLYM?

Do insiders & institutionals hold more shares of NRIX or CLYM?

Do analysts rate NRIX or CLYM?

Which has more volatility & risk, NRIX or CLYM?

Which has stronger valuation and earnings, NRIX or CLYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools